PRESS RELEASE: IVI’s Updated RA Model Examines New Treatment Options, Treatment Effects and Cost Estimates

IVI has just released the latest update to the organization's Rheumatoid Arthritis (RA) Value Assessment Model. The updated model now incorporates additional treatment options (triple therapy, Janus Kinase (JAK) inhibitors, sarilumab, and biosimilars), updated treatment effect estimates based on additional randomized controlled trial (RCT) evidence, and updated cost estimates. The model is also designed to [...]

2020-01-07T00:30:08-06:00January 7th, 2020|IVI News, Press|

PRESS RELEASE: IVI Research Brief Discusses Limitations of ICER’s Analysis for JAK Inhibitors

As part of its Value Blueprints series, IVI’s latest research brief grapples with a question prompted by ICER’s recent assessment of RA therapies: Do conventional value assessments address the questions most relevant to real-world decisions about treatment pathways for chronic diseases? In the brief, the authors discuss how the failure of ICER’s analysis to evaluate [...]

2019-12-10T13:20:31-06:00December 10th, 2019|IVI News, Press|

PRESS RELEASE: IVI Receives Eugene Washington PCORI Engagement Award

IVI has been selected by the Patient-Centered Outcomes Research Institute (PCORI) for a Eugene Washington PCORI Engagement Award. The $50,000 award will be used to convene a multi-stakeholder forum in February 2020 to review established and emerging approaches for improving value assessment and then identify and prioritize potential areas for research investment and collaborative solutions. [...]

2019-10-08T10:49:54-06:00October 8th, 2019|IVI News, Press|

PRESS RELEASE: How Structural Uncertainty Impacts Value Estimates

In a new Value Blueprints research brief, IVI explores the concept of “structural uncertainty,” an important source of uncertainty that is not generally measured or addressed in cost-effectiveness models. In this research brief, we use the IVI-RA model to demonstrate how different structural assumptions lead to varying cost-effectiveness estimates. As our findings make clear, it [...]

2019-10-11T11:43:24-06:00September 4th, 2019|IVI News, Press, Publications, Research|

PRESS RELEASE: IVI Illustrates “Insurance Value” Using IVI-RA Model in Latest Research Brief

In a new Value Blueprints research brief, IVI explores the novel concept of “Insurance Value.” New medical technologies not only benefit patients, but also healthy people at risk of future illness. The insurance value arising from the decreased physical risk from illness is a potentially important dimension to consider in value assessment, especially when decisions [...]

2019-10-11T11:43:53-06:00July 25th, 2019|IVI News, Press, Publications, Research|

PRESS RELEASE: IVI Releases Public Comments on Non-Small Cell Lung Cancer Value Tool

Thank you for your comments! IVI has released all public feedback received during the open comment period for the IVI-NSCLC model - our open-source platform to assess therapy sequences for EGFR+ non-small cell lung cancer. In the spirit of IVI's mission of collaboration, commitment to transparency, and dedication to iterative improvement, we look forward to [...]

2019-07-18T13:08:44-06:00July 18th, 2019|IVI News, Press|

Heard at ISPOR: Wide Ranging Podcast with IVI on Advanced Value Assessment Methods and the QALY Controversy

The IVI team sat down with the Journal of Clinical Pathways while at ISPOR for an in-depth discussion about why advanced value assessment is needed and how it’s progressing. The team also discussed the QALY – what it is and whether it can be improved. To listen to the podcast or read the transcript, click [...]

2019-06-12T12:48:09-06:00June 12th, 2019|IVI News, Press|

PRESS RELEASE: IVI Launches New Research Brief Series “Value Blueprints”

IVI launches a new research brief series to present research findings and method insights from the OSVP. Let’s sparks a conversation into next-gen value assessment. Read the full press release here.

2019-10-11T11:44:18-06:00May 20th, 2019|IVI News, Press, Publications, Research|

PRESS RELEASE: IVI Unveils New Value Assessment Model for Non-Small Cell Lung Cancer

IVI released our initial version of the new Open-Source Value Platform (OSVP) model for non-small cell lung cancer. Specifically, the model provides information on the relative value of sequential treatments for epidermal growth factor receptor positive (EGFR+), non-squamous non-small cell lung cancer (NSCLC). The entirety of the IVI-NSCLC model package, including detailed methods documentation, R [...]

2019-01-31T13:30:16-06:00January 31st, 2019|IVI News, Press|

PRESS RELEASE: IVI’s Patient Research Reveals Importance of Quality of Life in Assessing Non-Small Cell Lung Cancer Therapy Sequence Value

Los Angeles, CA – November 15, 2018 – The Innovation and Value Initiative (IVI) – a nonprofit dedicated to advancing the science and improving the practice of value assessment in healthcare – today released qualitative research evaluating what factors most impact the value of treatment to metastatic non-small cell lung cancer patients. According to the [...]

2018-11-15T16:00:32-06:00November 15th, 2018|IVI News, Press, Research|